- Home
- CBOE vs INSM Comparison
CBOE vs INSM Comparison
Compare CBOE & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBOE
- INSM
- Stock Information
- Founded
- CBOE 1973
- INSM 1988
- Country
- CBOE United States
- INSM United States
- Employees
- CBOE N/A
- INSM N/A
- Industry
- CBOE Investment Bankers/Brokers/Service
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- CBOE Finance
- INSM Health Care
- Exchange
- CBOE Nasdaq
- INSM Nasdaq
- Market Cap
- CBOE 25.6B
- INSM 29.0B
- IPO Year
- CBOE 2010
- INSM 2000
- Fundamental
- Price
- CBOE N/A
- INSM $163.54
- Analyst Decision
- CBOE Hold
- INSM Strong Buy
- Analyst Count
- CBOE 13
- INSM 19
- Target Price
- CBOE $234.15
- INSM $155.88
- AVG Volume (30 Days)
- CBOE 785.5K
- INSM 2.1M
- Earning Date
- CBOE 10-31-2025
- INSM 10-30-2025
- Dividend Yield
- CBOE 1.19%
- INSM N/A
- EPS Growth
- CBOE 18.01
- INSM N/A
- EPS
- CBOE 8.52
- INSM N/A
- Revenue
- CBOE $4,531,800,000.00
- INSM $398,105,000.00
- Revenue This Year
- CBOE N/A
- INSM $32.44
- Revenue Next Year
- CBOE $4.38
- INSM $123.99
- P/E Ratio
- CBOE $28.37
- INSM N/A
- Revenue Growth
- CBOE 18.98
- INSM 21.15
- 52 Week Low
- CBOE $187.30
- INSM $60.40
- 52 Week High
- CBOE $255.27
- INSM $166.44
- Technical
- Relative Strength Index (RSI)
- CBOE 50.73
- INSM 74.01
- Support Level
- CBOE $234.72
- INSM $161.34
- Resistance Level
- CBOE $246.64
- INSM $166.44
- Average True Range (ATR)
- CBOE 5.00
- INSM 4.36
- MACD
- CBOE 0.07
- INSM 0.23
- Stochastic Oscillator
- CBOE 46.04
- INSM 90.27
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.